Prelude Capital Management, LLC Sage Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

$1.39 Billion
Q2 2024

A detailed history of Prelude Capital Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 19,633 shares of SAGE stock, worth $136,645. This represents 0.02% of its overall portfolio holdings.

Number of Shares

19,633

Previous 18,193 7.92%

Holding current value

$136,645

Previous $340,000 37.35%

% of portfolio

0.02%

Previous 0.02%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $15,235 - $25,775	1,440 Added 7.92%	19,633 $213,000
Q1 2024 May 15, 2024	SELL	$18.62 - $26.95 $70,495 - $102,032	-3,786 Reduced 17.23%	18,193 $340,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $67,322 - $87,637	3,937 Added 21.82%	21,979 $476,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $151,168 - $442,044	9,025 Added 100.09%	18,042 $371,000
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $202,558 - $296,687	-4,983 Reduced 35.59%	9,017 $423,000
Q1 2023 May 15, 2023	BUY	$37.27 - $46.57 $73,720 - $92,115	1,978 Added 16.45%	14,000 $587,000
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $421,304 - $570,593	-13,084 Reduced 52.12%	12,022 $458,000
Q3 2022 Nov 14, 2022	BUY	$32.28 - $43.27 $4,293 - $5,754	133 Added 0.53%	25,106 $983,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $412,139 - $568,938	14,976 Added 149.8%	24,973 $807,000
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $307,007 - $456,962	9,997 New	9,997 $331,000
Q3 2021 Nov 15, 2021	SELL	$40.26 - $57.37 $193,731 - $276,064	-4,812 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $264,082 - $381,543	4,812 New	4,812 $273,000
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $535,103 - $732,860	-7,574 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $108,993 - $166,185	1,866 Added 32.69%	7,574 $655,000
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $114,917 - $174,485	-2,794 Reduced 32.86%	5,708 $349,000
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $220,626 - $366,861	8,502 New	8,502 $354,000
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $219,163 - $647,348	-8,381 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $172,716 - $444,189	2,870 Added 52.08%	8,381 $605,000
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $353,390 - $478,509	2,519 Added 84.19%	5,511 $773,000
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $472,287 - $547,805	2,992 New	2,992 $548,000
Q4 2018 Feb 14, 2019	SELL	$81.94 - $139.71 $148,966 - $253,992	-1,818 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$138.11 - $169.04 $170,013 - $208,088	-1,231 Reduced 40.37%	1,818 $257,000
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $280 - $351	-2 Reduced 0.07%	3,049 $477,000
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $117,003 - $147,901	-769 Reduced 20.13%	3,051 $491,000
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $3,643 - $10,040	-60 Reduced 1.55%	3,820 $629,000
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $238,232 - $343,457	3,880	3,880 $242,000

Others Institutions Holding SAGE

# of Institutions

217

Shares Held

48.2M

Call Options Held

854K

Put Options Held

195K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $414M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account

Prelude Capital Management, LLC Sage Therapeutics, Inc. Transaction History